PL2694116T3 - Nanocząstki na bazie lipidów - Google Patents

Nanocząstki na bazie lipidów

Info

Publication number
PL2694116T3
PL2694116T3 PL12767275T PL12767275T PL2694116T3 PL 2694116 T3 PL2694116 T3 PL 2694116T3 PL 12767275 T PL12767275 T PL 12767275T PL 12767275 T PL12767275 T PL 12767275T PL 2694116 T3 PL2694116 T3 PL 2694116T3
Authority
PL
Poland
Prior art keywords
lipid
based nanoparticles
nanoparticles
Prior art date
Application number
PL12767275T
Other languages
English (en)
Polish (pl)
Inventor
Ananth Annapragada
Jason L. Eriksen
Eric A. Tanifum
Indrani DASGUPTA
Stephen C. Cook
Original Assignee
Board Of Regents Of The University Of Texas System
Alzeca Biosciences, LLC
Board Of Regents Of The University Of Houston System
Texas Children's Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46966277&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2694116(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Board Of Regents Of The University Of Texas System, Alzeca Biosciences, LLC, Board Of Regents Of The University Of Houston System, Texas Children's Hospital filed Critical Board Of Regents Of The University Of Texas System
Publication of PL2694116T3 publication Critical patent/PL2694116T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0461—Dispersions, colloids, emulsions or suspensions
    • A61K49/0466—Liposomes, lipoprotein vesicles, e.g. HDL or LDL lipoproteins, phospholipidic or polymeric micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dispersion Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
PL12767275T 2011-04-06 2012-04-06 Nanocząstki na bazie lipidów PL2694116T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161472605P 2011-04-06 2011-04-06
PCT/US2012/032649 WO2012139080A2 (en) 2011-04-06 2012-04-06 Lipid-based nanoparticles
EP12767275.6A EP2694116B1 (en) 2011-04-06 2012-04-06 Lipid-based nanoparticles

Publications (1)

Publication Number Publication Date
PL2694116T3 true PL2694116T3 (pl) 2018-12-31

Family

ID=46966277

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12767275T PL2694116T3 (pl) 2011-04-06 2012-04-06 Nanocząstki na bazie lipidów

Country Status (14)

Country Link
US (1) US9801957B2 (enExample)
EP (2) EP3366313A1 (enExample)
JP (3) JP6212032B2 (enExample)
KR (2) KR102035187B1 (enExample)
CN (1) CN104144708B (enExample)
AU (3) AU2012239888B9 (enExample)
BR (1) BR112013025633A2 (enExample)
CA (1) CA2831480C (enExample)
DK (1) DK2694116T3 (enExample)
ES (1) ES2685824T3 (enExample)
MX (1) MX357227B (enExample)
PL (1) PL2694116T3 (enExample)
PT (1) PT2694116T (enExample)
WO (1) WO2012139080A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3366313A1 (en) 2011-04-06 2018-08-29 Board Of Regents Of the University Of Texas System Lipid-based nanoparticles
JP6130401B2 (ja) 2012-01-20 2017-05-17 アンナプラガダ，アナンス 医学画像を客観的に特徴付けるための方法および組成物
US9512092B2 (en) 2013-12-12 2016-12-06 Albert Einstein College Of Medicine, Inc. Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof
CN107106708B (zh) * 2014-10-08 2021-06-18 德克萨斯州儿童医院 使用脂质体进行的淀粉样蛋白斑mri成像
GB201509934D0 (en) 2015-06-08 2015-07-22 King S College London Nanoparticles
WO2017201091A1 (en) * 2016-05-16 2017-11-23 The Board Of Regents Of The University Of Texas System COMPOSITIONS FOR THE DELIVERY OF tRNA AS NANOPARTICLES AND METHODS OF USE THEREWITH
CN110022859B (zh) * 2016-11-30 2022-10-28 德克萨斯州儿童医院 具有独特的mr特征用于脂质体19f mri探针的亲水性氟化分子
EP3914230A4 (en) * 2019-01-24 2023-06-07 Alzeca Biosciences, Llc <SMALLCAPS/>? ? ?FUNCTIONALIZED LIPOSOMES FOR IMAGE MISFOLDED PROTEINS
CN115916263B (zh) * 2020-01-29 2025-10-03 德克萨斯儿童医院 用于淀粉样蛋白沉积mri的靶向对比剂
US11779664B2 (en) 2020-02-12 2023-10-10 Texas Children's Hospital Targeted contrast agents for MRI of alpha-synuclein deposition
CN115279424A (zh) * 2020-02-12 2022-11-01 德克萨斯儿童医院 用于α-突触核蛋白沉积MRI的靶向对比剂

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331751A (en) * 1980-11-17 1982-05-25 Eastman Kodak Company Electrically photosensitive materials and elements for photoelectrophoretic imaging processes
US5204085A (en) 1985-01-08 1993-04-20 Mallinckrodt Medical, Inc. Method for enhancing the safety of metal-ligand chelates as X-ray contrast agents
US5674468A (en) 1992-03-06 1997-10-07 Nycomed Imaging As Contrast agents comprising gas-containing or gas-generating polymer microparticles or microballoons
ZA952485B (en) 1994-03-28 1995-12-15 Nycomed Imaging As Liposomes
US6071532A (en) 1996-10-15 2000-06-06 Emory University Synthesis of glycophospholipid and peptide-phospholipid conjugates and uses thereof
DE60017787T2 (de) * 1999-11-30 2006-01-05 ARIZONA BOARD OF REGENTS, on behalf of THE UNIVERSITY OF ARIZONA, Tucson Strahlung-sensitive liposomen
AU2002211517A1 (en) * 2000-10-04 2002-04-15 California Institute Of Technology Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits
WO2002094191A2 (en) * 2001-05-23 2002-11-28 New York University Detection of alzheimer's amyloid by magnetic resonance imaging
US7138136B2 (en) 2002-03-05 2006-11-21 Cleveland State University Agglomerated particles for aerosol drug delivery
US7605182B2 (en) 2003-05-01 2009-10-20 Aposense Ltd. Compounds that selectively bind to membranes of apoptotic cells
US7208174B2 (en) * 2003-12-18 2007-04-24 Hoffmann-La Roche Inc. Liposome compositions
US20100031378A1 (en) 2008-08-04 2010-02-04 Edwards Joel A Novel gene disruptions, compositions and methods relating thereto
US8357351B2 (en) 2004-04-21 2013-01-22 Ananth Annapragada Nano-scale contrast agents and methods of use
US7713517B2 (en) 2004-04-21 2010-05-11 Marval Biosciences, Inc. Compositions and methods for enhancing contrast in imaging
WO2006026184A2 (en) * 2004-08-20 2006-03-09 Washington University Blood brain barrier permeation peptides
ATE493152T1 (de) * 2004-09-23 2011-01-15 Guerbet Sa Liposomale kontrastmittel für die cest-bildgebung
US9943481B2 (en) * 2005-05-26 2018-04-17 Biorest Ltd. Compositions and methods using same for delivering agents into a target organ protected by a blood barrier
US20070160658A1 (en) * 2005-10-20 2007-07-12 The Penn State Research Foundation Delivery system for diagnostic and therapeutic agents
WO2008054498A2 (en) * 2006-04-07 2008-05-08 The Board Of Trustees Of The University Of Illinois Hydrophilic polymer-conjugated lipids for peptide and protein folding disorders
US20090123047A1 (en) 2007-03-21 2009-05-14 Yfantis Spyros A Method and system for characterizing prostate images
EP1982733A1 (en) 2007-04-17 2008-10-22 Bayer Schering Pharma Aktiengesellschaft Use of a contrast agent for magnetic resonance imaging of endoleaks
US20110311457A1 (en) 2007-07-26 2011-12-22 Nanoscan Imaging, Llc Methods for imaging vascular inflammation using improved nanoparticle contrast agents
JP2011506325A (ja) 2007-12-05 2011-03-03 マーバル バイオサイエンシーズ インコーポレイテッド ナノスケールのコントラスト剤及びその使用方法
JP5647899B2 (ja) 2008-01-08 2015-01-07 ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ オリゴサッカリルトランスフェラーゼを使用するポリペプチドの複合糖質化
ITMI20081052A1 (it) * 2008-06-10 2009-12-11 Univ Milano Bicocca Liposomi in grado di legare efficacemente il peptide beta-amiloide
WO2009152445A1 (en) * 2008-06-13 2009-12-17 Marval Biosciences, Inc. Imaging of atherosclerotic plaques using liposomal imaging agents
WO2010017094A2 (en) * 2008-07-31 2010-02-11 The General Hospital Corporation CURCUMIN DERIVATIVES FOR AMYLOID-β PLAQUE IMAGING
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
US20120003159A1 (en) 2009-03-19 2012-01-05 Board Of Regents Of The University Of Texas System Compositions and methods for enhancing contrast in imaging
WO2010115080A2 (en) * 2009-04-02 2010-10-07 The Johns Hopkins University Self-assembling peptides bearing organic electronic functionality and applications employing the same
EP2501696B1 (en) 2009-10-15 2016-12-28 Guerbet Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
EP2582674B1 (en) 2010-06-16 2014-10-01 Cymabay Therapeutics, Inc. Gpr120 receptor agonists and uses thereof
MX345504B (es) 2011-03-02 2017-02-02 Sensulin Llc Composiciones de vesicula.
EP3366313A1 (en) 2011-04-06 2018-08-29 Board Of Regents Of the University Of Texas System Lipid-based nanoparticles
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
JP6130401B2 (ja) 2012-01-20 2017-05-17 アンナプラガダ，アナンス 医学画像を客観的に特徴付けるための方法および組成物
WO2013164763A2 (en) 2012-04-30 2013-11-07 Innovative Health Diagnostics A biological complex specific for alzheimer's disease detection in vitro and use thereof
AU2014240042C1 (en) 2013-03-14 2019-09-05 Celltaxis, Llc Inhibitors of leukotriene A4 hydrolase
CN107106708B (zh) 2014-10-08 2021-06-18 德克萨斯州儿童医院 使用脂质体进行的淀粉样蛋白斑mri成像

Also Published As

Publication number Publication date
CA2831480A1 (en) 2012-10-11
US9801957B2 (en) 2017-10-31
AU2017232156A1 (en) 2017-10-12
JP2014523854A (ja) 2014-09-18
AU2012239888B2 (en) 2017-06-22
KR102035187B1 (ko) 2019-11-08
MX2013011231A (es) 2015-03-05
AU2017232156C1 (en) 2019-10-24
JP6533813B2 (ja) 2019-06-19
WO2012139080A2 (en) 2012-10-11
PT2694116T (pt) 2018-10-12
CN104144708B (zh) 2017-07-28
JP2019151664A (ja) 2019-09-12
ES2685824T3 (es) 2018-10-11
AU2012239888A2 (en) 2014-05-08
HK1203827A1 (en) 2015-11-06
JP6212032B2 (ja) 2017-10-18
KR20140074868A (ko) 2014-06-18
KR101973063B1 (ko) 2019-04-30
CN104144708A (zh) 2014-11-12
AU2019246775A1 (en) 2019-10-31
EP2694116A4 (en) 2015-06-03
AU2012239888A1 (en) 2013-11-07
EP3366313A1 (en) 2018-08-29
CA2831480C (en) 2020-09-29
KR20190031334A (ko) 2019-03-25
EP2694116A2 (en) 2014-02-12
MX357227B (es) 2018-07-02
EP2694116B1 (en) 2018-06-13
AU2012239888B9 (en) 2017-10-12
DK2694116T3 (en) 2018-09-03
WO2012139080A3 (en) 2014-05-01
US20120258044A1 (en) 2012-10-11
AU2017232156B2 (en) 2019-07-11
BR112013025633A2 (pt) 2017-08-08
JP2018035167A (ja) 2018-03-08

Similar Documents

Publication Publication Date Title
DK3798230T3 (en) Terapeutiske antistoffer
DK2691417T4 (en) Antistof fc-varianter
EP2755962A4 (en) AZAINDAZOLES
EP2754063A4 (en) EXTENSIBILITY OF THE SMB2 PROTOCOL
EP2723631A4 (en) QUADFOILER
EP2662268A4 (en) CAP MOUNTING STRUCTURE
EP2776444A4 (en) dihydropteridinones
PT2694116T (pt) Nanopartículas à base de lípidos
AP2014007621A0 (en) 2-Thiopyrimidinones
GB201103926D0 (en) Lock-alarm
SG11201402471SA (en) Photocatalyst-supporting structure
GB201101727D0 (en) Obuoy
AU5031P (en) BESYS Beschorneria yuccoides
AU5026P (en) Goldstrike Agapanthus inapertus
AU4540P (en) BUNNAN Baloskion tetraphyllum
GB201102529D0 (en) Fine B-Day
GB201109229D0 (en) New uses
GB201101204D0 (en) Swiftnut
GB201104240D0 (en) Quantocosmocrypt
GB201100055D0 (en) Evac-sac
GB201100168D0 (en) SecuriPad
GB201102443D0 (en) Atompower
GB201100308D0 (en) CrossPic
GB201100359D0 (en) Fedorak-a-lope
GB201101047D0 (en) VibroPred